Everest Medicines grants options and awards to chairman Yifang Wu

On October 10, 2025, Everest Medicines granted 1,237,374 options to Yifang Wu under its post-IPO share option scheme. The exercise price for these options is HK$56.63, while the market price of the shares on the grant date was HK$53.20 per share. These options will vest equally over four years, with the first vesting date on October 9, 2026, and the exercise period extending seven years from the grant date. No performance targets are attached to these options.

Additionally, on the same date, the board proposed to grant 530,303 awards to Wu under the pre-IPO ESOP. This grant is subject to Wu's acceptance and independent shareholders' approval at a general meeting. Similar to the options, these awards will vest equally over four years, with the first vesting date on October 9, 2026, and no purchase price or performance targets attached. The market price of the shares on the proposed grant date was HK$53.20 per share.

The proposed award grant constitutes a non-exempt connected transaction, requiring reporting, announcement, circular, and independent shareholders' approval. As of this announcement, 2,415,111 shares remain available for grant under the post-IPO share option scheme, and 1,530,335 shares under the pre-IPO ESOP, accounting for these new grants.